Thermo Fisher Scientific
Top Five Articles on 360Dx Last Week: Becton Dickinson's Spinoff Plans; More
Last week, readers were most interested in a story about BD's plan to separate its Biosciences and Diagnostics Solutions business by the end of 2026.
The company reported a 5 percent increase in Q4 2024 revenues and flat full-year revenues, but guided for 3 percent to 4 percent organic revenue growth in 2025.
Abbott, BioMérieux, Cepheid, Roche, Others Gain FDA 510(k) Clearances in December
The FDA granted marketing clearances for infectious disease tests, updates to a digital pathology system, and immunoassays for chronic diseases.
JP Morgan Healthcare Conference, Day 2: Thermo Fisher, Labcorp, Hologic, CareDx, More
Highlights from the first day included updates from several firms about their China businesses and M&A strategies.
Thermo Fisher Scientific, BioMérieux, Cepheid, Others Gain 510(k) Clearances in November
The US Food and Drug Administration granted clearances to tests for infectious diseases, drug resistances, and chronic diseases, among other clearances.